A detailed history of Victory Capital Management Inc transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 39,251 shares of ARWR stock, worth $744,198. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,251
Previous 41,090 4.48%
Holding current value
$744,198
Previous $1.07 Million 28.87%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$19.36 - $29.54 $35,603 - $54,324
-1,839 Reduced 4.48%
39,251 $759,000
Q2 2024

Aug 05, 2024

BUY
$21.87 - $28.24 $361,598 - $466,920
16,534 Added 67.33%
41,090 $1.07 Million
Q1 2024

May 03, 2024

BUY
$27.21 - $39.48 $74,092 - $107,504
2,723 Added 12.47%
24,556 $702,000
Q4 2023

Feb 05, 2024

SELL
$21.2 - $31.03 $574,838 - $841,378
-27,115 Reduced 55.4%
21,833 $668,000
Q3 2023

Nov 06, 2023

BUY
$26.2 - $36.08 $101,918 - $140,351
3,890 Added 8.63%
48,948 $1.32 Million
Q2 2023

Jul 27, 2023

SELL
$25.16 - $41.38 $119,686 - $196,844
-4,757 Reduced 9.55%
45,058 $1.61 Million
Q1 2023

May 02, 2023

SELL
$23.68 - $38.51 $260,953 - $424,380
-11,020 Reduced 18.11%
49,815 $1.27 Million
Q4 2022

Feb 10, 2023

SELL
$28.0 - $40.56 $18,088 - $26,201
-646 Reduced 1.05%
60,835 $2.47 Million
Q4 2022

Feb 09, 2023

SELL
$28.0 - $40.56 $43,064 - $62,381
-1,538 Reduced 2.44%
61,481 $2.49 Million
Q3 2022

Nov 02, 2022

BUY
$29.63 - $48.31 $395,560 - $644,938
13,350 Added 26.88%
63,019 $2.08 Million
Q2 2022

Aug 01, 2022

BUY
$27.79 - $50.61 $95,097 - $173,187
3,422 Added 7.4%
49,669 $1.75 Million
Q1 2022

May 04, 2022

BUY
$39.62 - $69.97 $380,748 - $672,411
9,610 Added 26.23%
46,247 $1.9 Million
Q4 2021

Feb 07, 2022

SELL
$58.09 - $82.51 $195,240 - $277,316
-3,361 Reduced 8.4%
36,637 $2.43 Million
Q3 2021

Nov 02, 2021

SELL
$58.38 - $84.96 $195,281 - $284,191
-3,345 Reduced 7.72%
39,998 $2.5 Million
Q2 2021

Aug 03, 2021

SELL
$62.15 - $90.32 $311,744 - $453,045
-5,016 Reduced 10.37%
43,343 $3.59 Million
Q1 2021

May 04, 2021

SELL
$61.35 - $90.47 $180,491 - $266,162
-2,942 Reduced 5.73%
48,359 $3.21 Million
Q4 2020

Feb 01, 2021

SELL
$43.82 - $85.37 $107,753 - $209,924
-2,459 Reduced 4.57%
51,301 $3.94 Million
Q3 2020

Nov 09, 2020

SELL
$33.21 - $51.27 $450,427 - $695,375
-13,563 Reduced 20.15%
53,760 $2.32 Million
Q2 2020

Aug 07, 2020

BUY
$26.12 - $43.27 $34,739 - $57,549
1,330 Added 2.02%
67,323 $2.91 Million
Q1 2020

May 04, 2020

SELL
$20.56 - $63.12 $17,887 - $54,914
-870 Reduced 1.3%
65,993 $1.9 Million
Q4 2019

Feb 06, 2020

BUY
$28.14 - $73.01 $55,942 - $145,143
1,988 Added 3.06%
66,863 $4.24 Million
Q4 2019

Feb 04, 2020

SELL
$28.14 - $73.01 $1.05 Million - $2.72 Million
-37,263 Reduced 36.48%
64,875 $2.72 Million
Q3 2019

Nov 12, 2019

BUY
$26.26 - $34.86 $2.62 Million - $3.47 Million
99,625 Added 3964.39%
102,138 $2.88 Million
Q4 2018

Feb 05, 2019

SELL
$10.74 - $19.7 $5,144 - $9,436
-479 Reduced 16.01%
2,513 $31,000
Q3 2018

Nov 01, 2018

BUY
$14.0 - $20.3 $5,502 - $7,977
393 Added 15.12%
2,992 $57,000
Q2 2018

Aug 02, 2018

SELL
$6.37 - $14.02 $6,370 - $14,020
-1,000 Reduced 27.79%
2,599 $35,000
Q2 2017

Aug 07, 2017

BUY
N/A
3,599
3,599 $6,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.01B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.